ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · Real-Time Price · USD

29.50

+0.46 (1.58%)

At close: Aug 21, 2026, 4:00 PM EDT

30.10

+0.60 (2.03%)

Pre-market: Aug 24, 2026, 7:15 AM EDT

ACADIA Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	384.99	177.7	319.59	188.66	114.85	147.44
Short-Term Investments	571.49	641.99	436.4	250.21	301.98	373.27
Cash & Short-Term Investments	956.47	819.69	755.99	438.87	416.82	520.71
Cash Growth	25.52%	8.43%	72.26%	5.29%	-19.95%	-17.60%
Accounts Receivable	150.64	121.46	98.74	98.27	62.2	64.37
Other Receivables	15.69	26.77	5.96	4.08	0.89	0.98
Receivables	166.33	148.23	104.7	102.35	63.08	65.34
Inventory	32.37	34.67	21.95	35.82	6.64	7.88
Prepaid Expenses	69.37	59.53	55.68	39.09	21.4	23.89
Total Current Assets	1,225	1,062	938.32	616.13	507.94	617.82
Property, Plant & Equipment	86.53	54.87	50.79	56.47	61.59	66.32
Long-Term Investments	-	-	-	-	-	3.6
Other Intangible Assets	103.45	108.89	119.78	65.49	-	-
Long-Term Deferred Tax Assets	240.68	249.88	-	-	-	-
Other Long-Term Assets	87.7	88.45	78.87	10.87	18.28	12.38
Total Assets	1,743	1,564	1,188	748.96	587.81	700.12

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	44.57	10.9	16.19	17.54	12.75	6.88
Accrued Expenses	302.56	254.27	254.44	196.16	103.58	80.89
Current Portion of Leases	14.31	11.63	9.96	9.41	9.31	8.3
Current Income Taxes Payable	-	0.3	12.02	1.56	-	-
Other Current Liabilities	-	-	102.26	29.58	-	-
Total Current Liabilities	361.44	277.11	394.87	254.25	125.63	96.07
Long-Term Leases	59.55	40.55	42.04	47.8	52.7	56.13
Other Long-Term Liabilities	15.31	19.14	18.06	15.15	9.07	7.03
Total Liabilities	436.29	336.81	454.96	317.2	187.4	159.23

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	3,086	3,039	2,937	2,863	2,771	2,695
Retained Earnings	-1,778	-1,813	-2,204	-2,431	-2,370	-2,154
Comprehensive Income & Other	-0.96	1.45	0.29	0.02	-0.98	-0.19
Shareholders' Equity	1,307	1,227	732.79	431.76	400.41	540.89
Total Liabilities & Equity	1,743	1,564	1,188	748.96	587.81	700.12

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	73.85	52.19	52	57.21	62	64.43
Net Cash (Debt)	882.62	767.5	704	381.66	354.82	456.28
Net Cash Growth	25.07%	9.02%	84.46%	7.56%	-22.23%	-21.66%
Net Cash Per Share	5.12	4.52	4.23	2.33	2.19	2.84
Filing Date Shares Outstanding	172.31	170.49	166.79	164.77	162.23	161.2
Total Common Shares Outstanding	172.13	170.31	166.71	164.65	162.06	161.01
Working Capital	863.11	785	543.45	361.87	382.31	521.76
Book Value Per Share	7.59	7.21	4.40	2.62	2.47	3.36
Tangible Book Value	1,203	1,118	613.01	366.27	400.41	540.89
Tangible Book Value Per Share	6.99	6.57	3.68	2.22	2.47	3.36
Machinery	-	9.09	10.16	10.42	10.42	10.54
Construction In Progress	-	3.26	0.52	-	-	-
Leasehold Improvements	-	4.64	3.75	3.75	3.7	3.7

SEC Filings: 10-K · 10-Q